Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | VDAC2 | P45880 | 1/20 | 0.47 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14447196 | 0.94 | GAA (0.53) | MEN1KMT2AVDAC2SLC7A11GAA | |
| SCHEMBL15457101 | 0.82 | GBA1 (0.50) | CFTRL3MBTL1GBA1LMNAMAPT | |
| SCHEMBL13633632 | 0.82 | VDAC2 (0.69) | VDAC2SLC7A11GAAGBA1LMNA | |
| SCHEMBL15457056 | 0.80 | CACNA2D1 (0.65) | MEN1KMT2ACFTRL3MBTL1ALDH1A1 | |
| SCHEMBL4457790 | 0.80 | CACNA2D1 (0.61) | MEN1KMT2AVDAC2SLC7A11L3MBTL1 | |
| SCHEMBL15457210 | 0.79 | GBA1 (0.47) | CFTRL3MBTL1ALDH1A1GBA1LMNA | |
| SCHEMBL13633735 | 0.79 | VDAC2 (0.51) | MEN1KMT2AVDAC2SLC7A11L3MBTL1 | |
| SCHEMBL15457183 | 0.79 | CACNA2D1 (0.51) | CFTRL3MBTL1GBA1MAPT | |
| SCHEMBL15457184 | 0.79 | CACNA2D1 (0.51) | CFTRL3MBTL1GBA1MAPT | |
| SCHEMBL3824460 | 0.79 | CACNA2D1 (0.51) | CFTRL3MBTL1GBA1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-8518959-B2 | Quinoxaline derivatives as antitumor agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518959-B2 | Quinoxaline derivatives as antitumor agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-7615554-B2 | Erastin and erastin binding proteins, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615554-B2 | Erastin and erastin binding proteins, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | MEN1 4713/4885KMT2A 4386/4885VDAC2 553/4885 |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | VDAC3, VDAC2, VDAC1 | MEN1 2178/4885KMT2A 3575/4885VDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.